These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 8968214)

  • 1. Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy: immune mechanisms and update on current therapies.
    van der Meché FG; van Doorn PA
    Ann Neurol; 1995 May; 37 Suppl 1():S14-31. PubMed ID: 8968214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Future developments in the treatment of immune-mediated polyneuropathies.
    van der Meché FG; van Doorn PA
    Eur Neurol; 1997; 38(3):230-7. PubMed ID: 9363836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy: pathogenesis and treatment.
    Koski CL
    Semin Neurol; 1994 Jun; 14(2):123-30. PubMed ID: 7984827
    [No Abstract]   [Full Text] [Related]  

  • 4. [Immunopathology and treatments of Guillain-Barré syndrome and of chronic inflammatory demyelinating polyneuropathy].
    Radziwill AJ; Kuntzer T; Steck AJ
    Rev Neurol (Paris); 2002 Mar; 158(3):301-10. PubMed ID: 11976589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoantibodies to peripheral nerve glycosphingolipids SPG, SLPG, and SGPG in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy.
    Yuki N; Tagawa Y; Handa S
    J Neuroimmunol; 1996 Oct; 70(1):1-6. PubMed ID: 8862128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies.
    Ho TW; Mishu B; Li CY; Gao CY; Cornblath DR; Griffin JW; Asbury AK; Blaser MJ; McKhann GM
    Brain; 1995 Jun; 118 ( Pt 3)():597-605. PubMed ID: 7600081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A critical review of therapies in acute and chronic inflammatory demyelinating polyneuropathies.
    Pollard JD
    Muscle Nerve; 1987; 10(3):214-21. PubMed ID: 3031499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of immune-mediated, dysimmune neuropathies.
    Finsterer J
    Acta Neurol Scand; 2005 Aug; 112(2):115-25. PubMed ID: 16008538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Acquired demyelinating neuropathies].
    Hahn AF
    Rev Prat; 2000 Apr; 50(7):724-30. PubMed ID: 10853551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy.
    Gorson KC; Allam G; Ropper AH
    Neurology; 1997 Feb; 48(2):321-8. PubMed ID: 9040714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of chronic immune-mediated polyneuropathies. State of the art and perspectives].
    Léger JM; Chassande B
    Ann Med Interne (Paris); 2000 May; 151 Suppl 1():1S19-23. PubMed ID: 10896984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies.
    Lehmann HC; Hartung HP
    J Neuroimmunol; 2011 Feb; 231(1-2):61-9. PubMed ID: 21056913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The mechanism of action of intravenous immunoglobulin in patients with chronic inflammatory demyelinating polyneuropathy.
    Brand A; Van Doorn PA; Rossi F; Kazatchkine MD; Vermeulen M
    Prog Clin Biol Res; 1990; 337():405-9. PubMed ID: 2353004
    [No Abstract]   [Full Text] [Related]  

  • 14. Peripheral nerve proteins as potential autoantigens in acute and chronic inflammatory demyelinating polyneuropathies.
    Lim JP; Devaux J; Yuki N
    Autoimmun Rev; 2014 Oct; 13(10):1070-8. PubMed ID: 25172243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous immunoglobulin treatment in multifocal motor neuropathy and other chronic immune-mediated neuropathies.
    Comi G; Nemni R; Amadio S; Galardi G; Leocani L
    Mult Scler; 1997 Apr; 3(2):93-7. PubMed ID: 9291161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of autoimmune neuromuscular diseases with high-dose intravenous immune globulin.
    Soueidan SA; Dalakas MC
    Pediatr Res; 1993 Jan; 33(1 Suppl):S95-100. PubMed ID: 8433882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guillain-Barré syndrome.
    Hahn AF
    Lancet; 1998 Aug; 352(9128):635-41. PubMed ID: 9746040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The spectrum of immune responses to Campylobacter jejuni and glycoconjugates in Guillain-Barré syndrome and in other neuroimmunological disorders.
    Enders U; Karch H; Toyka KV; Michels M; Zielasek J; Pette M; Heesemann J; Hartung HP
    Ann Neurol; 1993 Aug; 34(2):136-44. PubMed ID: 8338338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases.
    Stangel M; Toyka KV; Gold R
    Arch Neurol; 1999 Jun; 56(6):661-3. PubMed ID: 10369303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recent acquisitions in the treatment of chronic immune-mediated polyneuropathies].
    Léger JM; Viala K
    Rev Neurol (Paris); 2004 Feb; 160(2):205-10. PubMed ID: 15034478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.